Meta-analysis of protective efficacy of the monovalent and the pentavalent rotavirus vaccines

Abstract

Objective To evaluate the vaccine protective efficacy (VE) of two mainstream rotavirus vaccines, Rotarix and RotaTeq, against severe rotavirus gastroenteritis (SRVGE) and any-severity rotavirus gastroenteritis (any-severity RVGE). Methods Literatures of the randomized controlled trial (RCT) studies on VE for the two kinds of rotavirus vaccine were retrieved in the period of January 2006 to October 2017. RevMan 5.3 and STATA 11.0 software were employed to manipulate the pooled data of included literatures. Results A total of 12 RCT studies and 53 573 subject were included. The pooled VE against SRVGE was 85% (95%CI: 74%-92%). In developed countries or regions, the pooled VE against SRVGE was 92% (95%CI: 88%-94%). In Guangxi, China, the value reached 75% (95%CI: 63%-83%). The pooled VE against any-severity RVGE was 67% (95%CI: 53%-77%). In developed countries or regions, the pooled VE against any-severity achieved 76% (95%CI: 72%-80%) and that in Guangxi Autonomous Region, China was 64% (95%CI: 54%-72%). Conclusions Both rotavirus vaccines can provide effective protection against SRVGE and protective effect against any-severity RVGE. Key words: Rotavirus vaccines; Meta-analysis; Vaccine efficacy